Prospective surveillance study of conservative kidney care in the UK and the Republic of Ireland: a British Paediatric Surveillance Unit study Authors: Lucy Plumb, Manish D Sinha, Anna Casula, Tom Gray, Carol Inward, Heather Maxwell, James Medcalf, Fergus J Caskey Published: 2026 ABSTRACT AbstractObjectiveFor most children with kidney failure, a decision is made to commence kidney replacement therapies (KRT); however, little is known about children for whom a decision is made to manage their kidney condition conservatively, without the use of KRT. This study’s aim was to determine the incidence of children<16 years reaching kidney failure who received conservative kidney care and to describe their characteristics, care and outcomes.Setting and designWe conducted a prospective study in the UK and the Republic of Ireland (September 2020 to October 2022) through the British Paediatric Surveillance Unit.ResultsOver the surveillance period, 27 confirmed cases were reported (25 in the UK, 56% male). The median age at notification was 2.6 (IQR 0.3–8.7) years; 52% were white, 41% Asian and 7% of black ethnicity. The median number of comorbidities recorded was 5 (IQR 2–7). All children were referred to nephrology; 92% were referred to palliative care. Most (67%) were in kidney failure by the time treatment discussions commenced. Few (<5) received a trial of KRT. After 12 months, 18 children (73%) had died, 5 remained on conservative management and 2 started KRT.ConclusionChildren receiving conservative kidney care account for approximately one-tenth of all incident paediatric kidney failure in the UK. While families receive specialist and palliative care support, further investigation is needed to understand whether treatment discussions could occur in a timelier fashion. As a vulnerable group of children, routine national data capture, as for the KRT-treated cohort, would support standardisation of care, audit and benchmarking.Keywords: Data Collection, Epidemiology, Nephrology, Paediatrics, Palliative Care WHAT IS ALREADY KNOWN ON THIS TOPIC Children who reach kidney failure may be treated with kidney replacement therapies (KRT) such as dialysis or kidney transplantation, or conservatively, without the use of KRT. Children who reach kidney failure may be treated with kidney replacement therapies (KRT) such as dialysis or kidney transplantation, or conservatively, without the use of KRT. In the UK, children receiving long-term (>90 days) KRT are captured nationally through the UK Renal Registry, which allows audit and research of their care and outcomes. In the UK, children receiving long-term (>90 days) KRT are captured nationally through the UK Renal Registry, which allows audit and research of their care and outcomes. Very little is known about children for whom a decision is made to conservatively manage their kidney failure, in the UK or globally. Very little is known about children for whom a decision is made to conservatively manage their kidney failure, in the UK or globally. WHAT THIS STUDY ADDS This study suggests the incidence of conservatively managed kidney failure among UK children is 1.06 (95% CI 0.56 to 1.81) per million of the age-related population. This study suggests the incidence of conservatively managed kidney failure among UK children is 1.06 (95% CI 0.56 to 1.81) per million of the age-related population. Children who reach kidney failure for whom a decision is made to conservatively manage their kidney condition account for approximately one-tenth of the incident UK childhood kidney failure population. Children who reach kidney failure for whom a decision is made to conservatively manage their kidney condition account for approximately one-tenth of the incident UK childhood kidney failure population. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Children with kidney failure who receive conservative care can be identified on a national level. Routine data capture processes should be expanded to capture these children via registries to support audit, research and quality improvement for this cohort, ultimately to improve patient care. Children with kidney failure who receive conservative care can be identified on a national level. Routine data capture processes should be expanded to capture these children via registries to support audit, research and quality improvement for this cohort, ultimately to improve patient care. Given the significant burden of extrarenal disease experienced by these children, timely, cross-specialty discussions are necessary when considering kidney failure treatment options. Given the significant burden of extrarenal disease experienced by these children, timely, cross-specialty discussions are necessary when considering kidney failure treatment options. Introduction Due to medical advances, there are an increasing number of children surviving with multiple organ impairments, with some reaching kidney failure.1 Progression to kidney failure is associated with a higher mortality risk compared with the general paediatric population2 and is life-limiting,3 requiring kidney replacement therapies (KRT) such as dialysis or kidney transplantation for long-term survival. Although KRT is considered an acceptable option for most children, for some, KRT may not be in their best interests: ‘a weighing of expected burdens and benefits of that intervention for a particular child’.4 Instead, conservative kidney care, defined by Kidney Disease Improving Global Outcomes (KDIGO) as the ‘planned, holistic, patient-centred care for individuals with kidney failure that does not include dialysis, instead focusing on symptom management and quality of life’,5 may be considered the most appropriate treatment. For most children with kidney failure, a decision is made to commence KRT, which is reflected in the increased prevalence of KRT use worldwide; such children are often captured in national and global registries and their care and outcomes are well defined. However, little is known about children for whom a decision is made not to pursue KRT and to instead opt for conservative care. These children are seldom captured in kidney registries and therefore little is known about the care they receive, their outcomes and the decisions surrounding treatment. The aim of this study was therefore to identify and describe incident children across the UK and the Republic of Ireland with kidney failure for whom a decision is made to conservatively manage their kidney failure and to describe factors influencing the decision for conservative care and their outcomes. Methods We conducted a prospective surveillance study of conservative care in kidney failure in children under 16 years of age in the UK and the Republic of Ireland from 1 September 2020 to 31 October 2022 (26 months) via the British Paediatric Surveillance Unit (BPSU) monthly electronic notification system. The BPSU is a robust surveillance platform, established specifically to monitor rare diseases.6 Paediatricians across the UK and the Republic of Ireland receive monthly emails notifying them of active studies and are asked to record whether they have seen a case or not. In 2020, the response rate was 88.3%.6 Case definition The case definition was developed with the support of the British Association for Paediatric Nephrology (BAPN). The analytical case definition was a child under the age of 16 years who met the following three criteria: The child has known or suspected chronic kidney disease (CKD). This was defined as abnormalities of kidney structure or function that are expected to be long-term or with little-to-no expectation of recovery.AND The child has known or suspected chronic kidney disease (CKD). This was defined as abnormalities of kidney structure or function that are expected to be long-term or with little-to-no expectation of recovery. AND The child has evidence of kidney failure as evidenced by either:A persistent (≥2 occasions) serum creatinine greater than 120 µmol/L in children<12 months of age.ORA persistent (≥2 occasions) estimated glomerular filtration rate (eGFR) of <15 mL/min/1.73m2 in children ≥12 months, calculated using the updated Schwartz calculation.7AND The child has evidence of kidney failure as evidenced by either: A persistent (≥2 occasions) serum creatinine greater than 120 µmol/L in children<12 months of age.OR A persistent (≥2 occasions) serum creatinine greater than 120 µmol/L in children<12 months of age. OR A persistent (≥2 occasions) estimated glomerular filtration rate (eGFR) of <15 mL/min/1.73m2 in children ≥12 months, calculated using the updated Schwartz calculation.7 A persistent (≥2 occasions) estimated glomerular filtration rate (eGFR) of <15 mL/min/1.73m2 in children ≥12 months, calculated using the updated Schwartz calculation.7 AND An active decision has been made not to pursue long-term KRT and to instead manage the child’s kidney disease conservatively.This could include children for whom the decision for conservative kidney care is based primarily on non-renal medical conditions.Children who received KRT for <90 days before deciding on conservative management could also be included. This criterion was included to capture children who may receive a trial of KRT before a decision for conservative management was made and who would not be captured by UK Renal Registry reporting. An active decision has been made not to pursue long-term KRT and to instead manage the child’s kidney disease conservatively. This could include children for whom the decision for conservative kidney care is based primarily on non-renal medical conditions. This could include children for whom the decision for conservative kidney care is based primarily on non-renal medical conditions. Children who received KRT for <90 days before deciding on conservative management could also be included. This criterion was included to capture children who may receive a trial of KRT before a decision for conservative management was made and who would not be captured by UK Renal Registry reporting. Children who received KRT for <90 days before deciding on conservative management could also be included. This criterion was included to capture children who may receive a trial of KRT before a decision for conservative management was made and who would not be captured by UK Renal Registry reporting. Questionnaires (at notification and 12-month follow-up) were developed and piloted with families and paediatricians (onlinesupplemental files 1 2). Clinicians who reported a case to the BPSU were contacted by the study team and sent a copy of the notification questionnaire via encrypted, password-protected email or by secure post. Reminder emails were sent to clinicians who submitted a case notification but had not completed a questionnaire during the study surveillance and 12-month follow-up period. Potential cases were reviewed and discussed with the notifying clinician to determine case status. The study was advertised via the BPSU and UK Renal Registry websites and to members of the BAPN and the British Association for Perinatal Medicine. Identifying information (NHS number, date of birth, sex) was retained for the duration of the study to ensure duplicate cases could be identified, following which time it was pseudonymised in accordance with UK Renal Registry practices. Comparator cohort data were obtained for UK children incident to long-term KRT during the study surveillance period. The UK Renal Registry collects, reports and analyses data from all UK paediatric nephrology centres on children with kidney failure who receive long-term KRT and is recognised as a robust, nationally representative dataset.8 Statistical analysis Incidence rates per million of the age-related population (pmarp) were estimated for the whole sample and devolved nation. Mid-year (2021) population estimates were used for denominator data, obtained from the Office for National Statistics (UK)9 and Central Statistics Office (Republic of Ireland).10 Baseline characteristics of the study cohort were described and comparisons with the incident KRT cohort made using chi-squared test (categorical variables) or Kruskal-Wallis test for non-parametric continuous variables. Unadjusted survival was examined using Kaplan-Meier curves. Results Over the surveillance period, we received 74 notifications to the study (figure 1). Of these, 33 were ineligible cases; eight were duplicate reports and in six cases, notifying clinicians could not be contacted after initially registering a suspected case with the BPSU. This resulted in 27 confirmed cases; most cases (55.6%) were notified by nephrologists, with 22.2% referred by neonatologists and 11.1% by general paediatricians (online supplemental figure 1). During the same timeframe, 241 children commenced long-term KRT in the UK. Flow diagram of case identification. BPSU, British Paediatric Surveillance Unit; KRT, kidney replacement therapies. Incidence The overall incidence of conservative care in UK children was 1.06 (95% CI 0.56 to 1.81) pmarp. In England, the incidence was 0.96 (95% CI 0.55 to 0.91); in Scotland, 2.19 (95% CI 0.60 to 5.61) pmarp and Northern Ireland 2.58 pmarp (95% CI 0.31 to 9.30). No cases were reported from Wales. The Republic of Ireland annual incidence was 0.91 (95% CI 0.02 to 5.09) pmarp. Demographics of study cohort Table 1 highlights the demographic characteristics of the incident conservatively managed cohort, both overall (UK and Republic of Ireland) and UK only; details of the incident cohort of UK children commencing KRT during the study period are available in online supplemental table 1. Children in the conservatively managed cohort were generally younger, with over one-third (n=10, 37%) of those in the conservative care cohort under 28 days of age, compared with<1% of the KRT-treated cohort. Similarly, children who received conservative care were referred to nephrology at a younger age (median 0.0 (IQR 0.0–3.6) years, UK cohort 0.0 (IQR 0.0-4.3) years) compared with those starting KRT (median 4.8 (IQR 0.2–10.0) years, online supplemental table 1). Differences in ethnicity distribution were seen by treatment status, with a higher proportion of children of Asian and Black ethnicity receiving conservative care. No differences were noted by primary kidney disease or socioeconomic deprivation. Children who received conservative care had a median eGFR of 47.8 (IQR 26.8–83.6) mL/min/1.73 m2 at diagnosis. Of the 13 children aged older than 2 years with data (n=10), 4 had CKD stages 1–2 (eGFR≥60 mL/min/1.73 m2) and 6 had CKD stages 3–4 at diagnosis (eGFR 15–59 mL/min/1/73 m2). Creatinine data were available for 12 of the 13 children under 2 years at kidney failure onset: at diagnosis, 7 had a creatinine of less than 120 µmol/L, while 5 had a creatinine of more than 120 µmol. The median creatinine at diagnosis for this group was 101.5 (IQR 71–160) µmol/L. For the KRT cohort, the median eGFR at first nephrology review was 13.9 (IQR 7.5–32.6) mL/min/1.73 m2. A high proportion of children who were conservatively managed reached kidney failure (eGFR <15 mL/min/1.73m2) within 90 days from first nephrology review (n=9, 40.9%); in the KRT cohort, almost a quarter (n=55, 22.2%) commenced KRT within the same timeframe. Table 1Demographics of the incident conservative kidney care study cohortTotal conservative care cohortUK conservative care cohortN2725Male sex12 (44.4)12 (48.0)Age group at kidney failure onset Neonate (<28 days)10 (37.0)9 (36.0) ≥28 days and <2 years3 (11.1)3 (12.0) 2 to <4 years2 (7.4)2 (16.7) 4 to <8 years5 (18.5)5 (18.5) 8 to <12 years4 (14.8)4 (16.0) 12 to <16 years3 (11.1)2 (8.0)Median age at first nephrology review (IQR)0.0 (0.0, 3.6)0.0 (0.0–4.3)Median age at kidney failureonset (IQR)2.6 (0.3, 8.7)2.6 (0.3–8.3)Ethnicity Asian11 (40.7)10 (40.0) Black2 (7.4)2 (8.0) White14 (51.9)13 (52.0) Other0 (0.0)0 (0.0) Missing0 (0.0)0 (0.0)UK-wide IMD quintile 1 (most deprived)9 (33.3)9 (36.0) 26 (22.2)6 (24.0) 32 (7.4)2 (8.0) 42 (7.4)2 (8.0) 5 (least deprived)4 (14.8)4 (16.0) Missing4 (14.8)2 (8.0)Primary kidney diagnosis* Familial/hereditary nephropathies7 (25.9)7 (28.0) Glomerular disease5 (18.5)4 (16.0) Miscellaneous disorders3 (11.1)3 (12.0) Systemic diseases affecting the kidney0 (0.0)0 (0.0) Tubulointerstitial disease12 (44.4)11 (44.0) Missing0 (0.0)0 (0.0)Kidney failure reached within 90 days of first nephrology review †10 (41.7)9 (40.9)Deaths as of 30 October 202318 (66.7)17 (68.0)*Grouped according to European Renal Association primary renal disease groupings.23†Missing late presentation data for three of the conservative care cohort (UK and Republic of Ireland).eGFR, estimated glomerular filtration rate; IMD, Indices of multiple deprivation; KRT, kidney replacement therapy. Demographics of the incident conservative kidney care study cohort Grouped according to European Renal Association primary renal disease groupings.23 Missing late presentation data for three of the conservative care cohort (UK and Republic of Ireland). eGFR, estimated glomerular filtration rate; IMD, Indices of multiple deprivation; KRT, kidney replacement therapy. 13 children managed conservatively (48.1%) were <2 years old at the time of reaching kidney failure. Of this cohort, 12 were known antenatally to have a kidney condition, with 1 case suspected. Over half (n=7, 5.8%) were born prematurely (<37 weeks). Information on coexisting disease was captured for the conservatively managed cohort (figure 2a–d). High proportions of coexisting disease were noted with a median number of listed comorbidities of 5 (IQR 2–7). Over half of the cohort were reported to have developmental delay, congenital and genetic conditions, with differences in distribution observed across age groups. Two children had no reported comorbidity: 1 was a neonate at time of reaching kidney failure while 1 was between 1 month and 2 years of age. (a–d) Proportion of children with coexisting disease captured for confirmed cases, according to age at kidney failure: (a) <28 days (n=10), (b) 28 days to <4 years (n=5), (c) 4 years to <10 years (n=7) and (d) 10 years to <16 years (n=5). Other comorbidities included respiratory disorders/pulmonary hypoplasia (n=4), skin (n=1), musculoskeletal/limb disorders (n=3) and haematological/vascular disorders (n=1). Two-thirds of children (n=18) had reached kidney failure when discussions regarding treatment commenced. All patients were referred to nephrology services; two children were not referred to palliative care (figure 3); both died shortly after birth. A second opinion was sought in one-third of cases. Clinicians were asked to list the multiprofessional support available to families during treatment discussions (online supplemental figure 2). Most commonly involved were nephrology (n=23, 85.2%), palliative care (n=22, 81.5%) and nursing support (n=20, 74.1%); hospice teams were involved in 12 cases (44.4%). Psychology team and social care involvement were limited to one-third of cases (n=9, 33.3%). Chaplaincy and Play therapy teams were involved in eight and six cases, respectively. Sankey diagram of patient care before and after kidney failure. Note that flows from a node (eg, ‘kidney failure’) represent the outcomes of individuals at that nodal point; they do not necessarily represent the flow of individuals from earlier nodes. The different colours represent potential stages of patient care before and after reaching kidney failure for the conservative kidney care cohort. All confirmed cases were referred to nephrology: the diagram differentiates those referred before and after reaching kidney failure. Missing nephrology referral date for three patients. Missing palliative care data for six patients, two not referred to palliative care, one had unknown palliative care referral status. KRT, kidney replacement therapies. Fewer than five children received a trial of KRT before withdrawal, and for this reason, reporting of results is limited. Treatment options included all forms of KRT, including continuous therapies. Reasons for discontinuation given included mechanical failure of dialysis and discontinuation following confirmation of a genetic diagnosis. Notifying clinicians were asked to record ‘yes’, ‘no’ or ‘unknown’ for factors implicated in the decision for conservative care. We also asked clinicians to cite factors most important for families during discussions (online supplemental figure 3). In general, priorities for families and clinicians broadly mirrored each other. Factors most frequently recorded by clinicians included quality of life (95.8% of those with data) and suffering of child (95.7%), as well as the prognosis of kidney (92.0%) and non-kidney conditions (85.2%). For families, clinicians reported quality of life, suffering of child (both 95.5%) and life-limiting nature of conditions (85.7%) as most frequently recorded. A higher proportion of clinicians recorded the lack of prospects for a kidney transplant in their decision-making compared with families (57.1% vs 38.9%). Religious/cultural beliefs, family social background or the child’s wishes were cited in ≤5 cases each. We recontacted notifying clinicians 12 months after their initial notification to determine patient outcomes. Follow-up information was available for 25 patients (93.0%). During follow-up, 18 children (72.0%) had died, 5 (20.0%) continued to receive conservative kidney management and 2 (8.0%) had started KRT (figure 3). The median time to death from reaching kidney failure was 45 (IQR 19–137) days (figure 4). By comparison, five children incident to KRT during the follow-up period had died (2.1%). Survival of the conservatively managed cohort from the date of reaching kidney failure. Discussion This study is the first prospective, nationally representative study to be undertaken to determine the incidence of conservatively managed kidney failure in children. Over a 2-year period, the annual incidence in UK children was 1.06 (95% CI 0.56 to 1.81) pmarp, and in Republic of Ireland 0.91 (0.02 to 5.09) pmarp. From the UK cases identified, conservatively managed children account for approximately one-tenth of incident children with kidney failure. Comparable estimates in the literature are limited. Over a 10-year period, the ItalKid registry identified 16 patients<20 years nationally who received conservative management of their kidney disease.11 In the UK, 15 children under the age of 2 years reached kidney failure and did not receive KRT between 1988 and 1 997.12 A retrospective study of paediatric French-speaking nephrology units identified 11.5% (n=50) of prevalent children managed for kidney failure over a 5-year period had KRT treatment withheld or withdrawn.13 Within Europe, the UK has one of the highest incidences of KRT start for children,14 15 suggesting that as a nation, we are more likely to offer KRT compared with other countries, which may explain the relatively low proportion of conservatively managed children overall. As Fauriel et al observed, the most common group of children to receive conservative kidney care were neonates<28 days of age,13 although they accounted for a lower proportion of our study cohort (36% vs 62%). In contrast to Fauriel et al, most children identified in our study were diagnosed with primary kidney conditions, with few experiencing acute insults. While no difference in socioeconomic position was noted between children incident to conservative kidney care and those starting KRT, differences in ethnic distribution were observed. This finding is paradoxical to that seen in US adults, where people of Black ethnicity are more likely to opt for life-extending treatments and less likely to communicate end-of-life preferences.16 17 In UK adults, no differences in socioeconomic position or ethnicity were noted for patients choosing conservative care compared with those opting for KRT.18 Coexisting disease was highly prevalent in our study cohort. Although data were unavailable for the KRT-managed cohort, comparison with historical data from the UK Renal Registry19 suggests that children receiving conservative kidney care have a higher burden of coexisting disease than those receiving KRT. This supports the hypothesis that children who receive conservative kidney care experience significant extrarenal comorbidities and aligns with our findings that for both families and clinicians, the prognosis of extrarenal disease is a key consideration in decision-making. In agreement with previous research,13 the most frequently recorded factor in treatment decision-making for both clinicians and families was the child’s perceived quality of life; additionally, the prognosis of both renal and non-renal conditions factored equally highly, highlighting the importance of accurate information and collaborative discussions across all specialties caring for the child. Interestingly, although guidance from KDIGO suggests social, psychological and spiritual support are key features of conservative kidney care,5 few families reportedly received this. National recommendations emphasise that children and young people with life-limiting conditions and their families may experience emotional and psychological distress during end-of-life care planning and management discussions.20 Understanding whether support from these professionals is warranted or threatens to overwhelm families during an emotive time requires further investigation and the perspectives of the child, family and multiprofessional team. According to national guidance, children at risk of developing kidney failure should be offered a choice of KRT or conservative management, with assessment recommended a year before therapy is likely to be needed.21 We identified that in two-thirds of cases, treatment discussions started only once the child had reached kidney failure. While almost one-third of our cohort were neonates, which will account for some of this finding, it doesn’t completely explain it, suggesting that efforts to support timelier treatment discussions may be required. This is the first national study to prospectively capture children reaching kidney failure for whom a decision for conservative kidney care is made; additionally, due to the robust data capture of the UK Renal Registry, we have been able to describe this cohort alongside incident children commencing KRT in the same timeframe, thus addressing an important research gap.22 This study benefitted from the use of the BPSU, an established disease surveillance platform which reaches all paediatricians registered with the Royal College of Paediatricians and Child Health on a monthly basis. However, limitations in our methodology must be recognised. Due to the COVID-19 pandemic, this study was delayed in starting until September 2020; it is possible that case reporting could have been affected by ongoing disruptions to research during this time. Despite every attempt to contact clinicians who had notified the BPSU of a potential case, we were unable to make contact and/or determine the case status of several notifications, which may have underestimated the incidence. We are aware of one case that was reported to the study but subsequently withdrawn as ongoing discussions led to a decision to commence KRT rather than opting for conservative management; this is not a limitation but highlights the dynamic and iterative nature of decision-making for families and health professionals; this too is reflected by the small number of children who commenced KRT in the study follow-up period. Due to limitations in our case definition, we will not have captured children with a long-term kidney condition who died before confirmatory blood tests. An analysis of congenital kidney outcomes using the National Congenital Anomaly and Rare Disease Registration Service registry is ongoing to understand this group in more detail. We relied on information from clinical teams to determine important factors for families when choosing conservative care, which may not accurately reflect their perspectives. It is also possible that kidney failure was not perceived as the main disease for some patients (by clinicians or the family) but rather as a coexisting disease. Finally, due to a lack of research support to advertise the study in the Republic of Ireland, we are unclear as to how nationally representative estimates are. It is important to note that children who received conservative kidney care differ from a sociodemographic and clinical perspective to children who received KRT during the study period, and that inferences between the two are limited due to the small numbers identified. This study was necessary due to the lack of routinely collected data on this vulnerable cohort; previously, only children receiving KRT benefitted from audit, research and benchmarking of care and outcomes through the UK Renal Registry. However, governance permissions have expanded to capture data on any child in the UK with chronic kidney disease, with progress being made towards real-time data feeds from all nephrology centres. Moving forward, it is vital that we work with clinical teams to ensure all children with kidney failure are captured, so as to support national quality assurance of care, irrespective of their treatment pathway. In conclusion, this study finds that children who commence conservative management for their kidney failure account for approximately one-tenth of the total UK childhood kidney failure population. While families choosing conservative kidney care often receive specialist and palliative care support, it is unclear whether discussions can occur in a timelier fashion and if additional multiprofessional support could be offered. Supplementary material Acknowledgements The authors are grateful to the British Paediatric Surveillance Unit (BPSU) Team for their help and support with this study and all the clinicians who submitted returns to the BPSU, without which this study would not have been possible. We thank in particular Richard Lynn, Jacob Avis and Farhana Ahmed for their support in set-up and study management. We thank all the UK paediatric nephrology units for providing data to the UK Renal Registry and thank the Scottish Renal Registry for sharing the data they collect and validate in Scotland. Our thanks go also to our patient and parent representatives for this study, who approved the study aims and design with the hope of providing more information to families making kidney treatment decisions. Footnotes Funding: This study was funded by the Children’s Research Fund and supported by Kidney Research UK: Paediatric research project grant (reference: Paed_RP_002_20180927). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants. This study and its design received approval from the UK Kidney Association patient council, patient representatives, the Health Research Authority Confidentiality Advisory Group (19/CAG/0190) and Research Ethics Committee (19/SW/0197), Public Benefit and Privacy Panel for Health and Social Care (NHS Scotland, reference:1920-0101) and the Privacy Advisory Committee (Northern Ireland). Approval for aggregate data from the corresponding incident kidney replacement therapies (KRT) population was obtained from the UK Renal Registry (reference: ILD 140) under their section 251 permissions for audit and research in England and Wales. Data from Scotland are provided by the Scottish Renal Registry and Northern Ireland by the Department for Health and Social Care for Northern Ireland. Data availability free text: Data collected on the conservative kidney care cohort were obtained without patient consent following approval from the Health Research Authority Confidentiality Advisory Group (19-CAG-0190) and Research Ethics Committee (19/SW/0197), Public Benefit and Privacy Panel for Health and Social Care (NHS Scotland, reference 1920-0101) and the Privacy Advisory Committee (Northern Ireland). These data are not publicly available. Aggregate data for the corresponding incident KRT population was obtained from the UK Renal Registry and may be made available on request to the UK Renal Registry. Data availability statement Data may be obtained from a third party and are not publicly available. References Associated Data Supplementary Materials Data Availability Statement Data may be obtained from a third party and are not publicly available.